Big Bull
2021-11-18
Good
Cassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":878532155,"tweetId":"878532155","gmtCreate":1637204802922,"gmtModify":1637204802922,"author":{"id":4094912318336650,"idStr":"4094912318336650","authorId":4094912318336650,"authorIdStr":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good </p></body></html>","htmlText":"<html><head></head><body><p>Good </p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/878532155","repostId":1161909759,"repostType":4,"repost":{"id":"1161909759","kind":"news","pubTimestamp":1637203262,"share":"https://www.laohu8.com/m/news/1161909759?lang=zh_CN&edition=full","pubTime":"2021-11-18 10:41","market":"us","language":"en","title":"Cassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161909759","media":"The Street","summary":"The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences","content":"<p>The biotech faces claims of manipulating research results of its Alzheimer’s drug.</p><p><blockquote>该生物技术公司面临操纵其阿尔茨海默氏症药物研究结果的指控。</blockquote></p><p> $Cassava Sciences (<b>SAVA</b>)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included the Securities and Exchange Commission, were investing claims the biotech manipulated research results of its experimental Alzheimer’s drug, simufilam.</p><p><blockquote>$木薯科学(<b>萨瓦</b>)周三，在披露“某些政府机构”（据报道包括美国证券交易委员会）正在投资声称该生物技术公司操纵其实验性阿尔茨海默病药物simufilam的研究结果后，美元暴跌。</blockquote></p><p> Shares of the Austin, Texas company were down more than 23% to $47.07 Wednesday.</p><p><blockquote>周三，这家位于德克萨斯州奥斯汀的公司股价下跌超过23%，至47.07美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ba12f81714da2c89bed996a8439c131d\" tg-width=\"882\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.</p><p><blockquote>Cassava在一份证券文件中表示，“某些政府机构要求我们向他们提供公司信息和文件”，《华尔街日报》援引知情人士的话称，该机构是SEC。</blockquote></p><p> \"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"</p><p><blockquote>Cassava表示：“我们一直在并将继续与政府当局合作。”“没有任何政府机构通知我们任何一方有任何不当行为。”</blockquote></p><p> The National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.</p><p><blockquote>据该公司首席执行官称，美国国立卫生研究院自2015年以来向Cassava及其学术合作者提供了2000万美元的药物开发资助，该公司也在审查这些说法。</blockquote></p><p> Cassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to halt to trials of simufilam.</p><p><blockquote>今年8月，Labaton Sucharow举报人代理业务的合伙人兼主席乔丹·托马斯(Jordan Thomas)向美国提交了一份公民请愿书，木薯科学公司卷入了争议。食品药品监督管理局试图停止simufilam的试验。</blockquote></p><p> On Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"</p><p><blockquote>周三，托马斯给代理美国国务卿写了一封信。美国食品和药物管理局珍妮特·伍德库克(Janet Woodcock)表示：“我的客户对Cassava Sciences最担心的事情似乎是真的。”</blockquote></p><p> Thomas identified his clients as David Bredt, former neuroscience research chief at Johnson & Johnson (<b>JNJ</b>) Report and Eli Lilly & Co. (<b>LLY</b>) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine</p><p><blockquote>托马斯确认他的客户是强生公司前神经科学研究主管大卫·布雷特（David Bredt）（<b>JNJ</b>）报告和礼来公司（<b>LLY</b>），以及威尔康奈尔医学院心脏病专家兼教授杰弗里·皮特</blockquote></p><p> \"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"</p><p><blockquote>托马斯说：“由于他们对simufilam和Cassava的相关研究的严重担忧，并冒着巨大的个人和职业风险，我的举报人客户以及其他著名的医生和科学家自愿公开了此事。”</blockquote></p><p> Bredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.</p><p><blockquote>Bredt和Pitt写道，Cassava的研究包括实验图像，这些图像似乎是使用Photoshop等软件操纵的。</blockquote></p><p> Thomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"</p><p><blockquote>托马斯说，“越来越多的证据表明，Cassava篡改了其研究和临床试验结果，欺骗了同行评审期刊，利用受污染的科学欺骗NIH和FDA批准拨款和临床试验。”</blockquote></p><p> In addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"</p><p><blockquote>此外，该公司“通过兜售其资助和临床试验而不披露其令人不安的研究实践来误导投资者，并向脆弱的阿尔茨海默病患者隐瞒有关其药物真实性质的重要信息。”</blockquote></p><p> The FDA has a duty, Thomas said, \"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"</p><p><blockquote>Thomas表示，FDA有责任“立即停止simufilam临床试验，对该公司的所有研究和临床试验结果进行严格审核，并向感兴趣的执法和监管机构报告该机构的调查结果。”</blockquote></p><p> Cassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.</p><p><blockquote>Cassava没有立即回应置评请求，但首席执行官雷米·栗林诚一郎表示，卖空者滥用了FDA的请愿程序。</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Stock Tumbles on News of SEC Investigation<blockquote>Cassava Sciences股价因SEC调查消息而暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Street</strong><span class=\"h-time small\">2021-11-18 10:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The biotech faces claims of manipulating research results of its Alzheimer’s drug.</p><p><blockquote>该生物技术公司面临操纵其阿尔茨海默氏症药物研究结果的指控。</blockquote></p><p> $Cassava Sciences (<b>SAVA</b>)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included the Securities and Exchange Commission, were investing claims the biotech manipulated research results of its experimental Alzheimer’s drug, simufilam.</p><p><blockquote>$木薯科学(<b>萨瓦</b>)周三，在披露“某些政府机构”（据报道包括美国证券交易委员会）正在投资声称该生物技术公司操纵其实验性阿尔茨海默病药物simufilam的研究结果后，美元暴跌。</blockquote></p><p> Shares of the Austin, Texas company were down more than 23% to $47.07 Wednesday.</p><p><blockquote>周三，这家位于德克萨斯州奥斯汀的公司股价下跌超过23%，至47.07美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ba12f81714da2c89bed996a8439c131d\" tg-width=\"882\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.</p><p><blockquote>Cassava在一份证券文件中表示，“某些政府机构要求我们向他们提供公司信息和文件”，《华尔街日报》援引知情人士的话称，该机构是SEC。</blockquote></p><p> \"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"</p><p><blockquote>Cassava表示：“我们一直在并将继续与政府当局合作。”“没有任何政府机构通知我们任何一方有任何不当行为。”</blockquote></p><p> The National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.</p><p><blockquote>据该公司首席执行官称，美国国立卫生研究院自2015年以来向Cassava及其学术合作者提供了2000万美元的药物开发资助，该公司也在审查这些说法。</blockquote></p><p> Cassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to halt to trials of simufilam.</p><p><blockquote>今年8月，Labaton Sucharow举报人代理业务的合伙人兼主席乔丹·托马斯(Jordan Thomas)向美国提交了一份公民请愿书，木薯科学公司卷入了争议。食品药品监督管理局试图停止simufilam的试验。</blockquote></p><p> On Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"</p><p><blockquote>周三，托马斯给代理美国国务卿写了一封信。美国食品和药物管理局珍妮特·伍德库克(Janet Woodcock)表示：“我的客户对Cassava Sciences最担心的事情似乎是真的。”</blockquote></p><p> Thomas identified his clients as David Bredt, former neuroscience research chief at Johnson & Johnson (<b>JNJ</b>) Report and Eli Lilly & Co. (<b>LLY</b>) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine</p><p><blockquote>托马斯确认他的客户是强生公司前神经科学研究主管大卫·布雷特（David Bredt）（<b>JNJ</b>）报告和礼来公司（<b>LLY</b>），以及威尔康奈尔医学院心脏病专家兼教授杰弗里·皮特</blockquote></p><p> \"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"</p><p><blockquote>托马斯说：“由于他们对simufilam和Cassava的相关研究的严重担忧，并冒着巨大的个人和职业风险，我的举报人客户以及其他著名的医生和科学家自愿公开了此事。”</blockquote></p><p> Bredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.</p><p><blockquote>Bredt和Pitt写道，Cassava的研究包括实验图像，这些图像似乎是使用Photoshop等软件操纵的。</blockquote></p><p> Thomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"</p><p><blockquote>托马斯说，“越来越多的证据表明，Cassava篡改了其研究和临床试验结果，欺骗了同行评审期刊，利用受污染的科学欺骗NIH和FDA批准拨款和临床试验。”</blockquote></p><p> In addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"</p><p><blockquote>此外，该公司“通过兜售其资助和临床试验而不披露其令人不安的研究实践来误导投资者，并向脆弱的阿尔茨海默病患者隐瞒有关其药物真实性质的重要信息。”</blockquote></p><p> The FDA has a duty, Thomas said, \"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"</p><p><blockquote>Thomas表示，FDA有责任“立即停止simufilam临床试验，对该公司的所有研究和临床试验结果进行严格审核，并向感兴趣的执法和监管机构报告该机构的调查结果。”</blockquote></p><p> Cassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.</p><p><blockquote>Cassava没有立即回应置评请求，但首席执行官雷米·栗林诚一郎表示，卖空者滥用了FDA的请愿程序。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation\">The Street</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161909759","content_text":"The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences (SAVA)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included the Securities and Exchange Commission, were investing claims the biotech manipulated research results of its experimental Alzheimer’s drug, simufilam.\nShares of the Austin, Texas company were down more than 23% to $47.07 Wednesday.\n\nCassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.\n\"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"\nThe National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.\nCassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to halt to trials of simufilam.\nOn Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"\nThomas identified his clients as David Bredt, former neuroscience research chief at Johnson & Johnson (JNJ) Report and Eli Lilly & Co. (LLY) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine\n\"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"\nBredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.\nThomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"\nIn addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"\nThe FDA has a duty, Thomas said, \"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"\nCassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.","news_type":1,"symbols_score_info":{"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":1110,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/878532155"}
精彩评论